Infectious Disease Doctors in Canton, OH Accepting Medicare

7 Infectious Disease doctors found. Showing 1 - 7

Amy Indorf, MD Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 1320 Mercy Dr Nw, Canton, OH 44708 Phone: 330-580-4706    Fax: 330-580-4707

Dr. Ronald Anthony Shubert, M.D. Internal Medicine - Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 3501 Tuscarawas St W, Canton, OH 44708 Phone: 330-453-3099    Fax: 330-453-3240

Badie Al Nemr, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 128 Wertz Ave Nw, Suite C, Canton, OH 44708 Phone: 330-454-7722    Fax: 330-454-7834

Kiran Afshan, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2600 6th St Sw, Canton, OH 44710 Phone: 330-363-2180    Fax: 330-363-2179

Jessica Schwan, AGNP Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 5216 Schuller Dr Ne, Canton, OH 44705 Phone: 330-413-3385

Dr. Gabriel R Galang, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 128 Wertz Avenue Nw, Suite C, Canton, OH 44708 Phone: 330-454-7722    Fax: 330-454-7834

Dr. Marcantonio Fiorentino, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 128 Wertz Ave Nw, Suite C, Canton, OH 44708 Phone: 330-454-7722    Fax: 330-454-7834

News Archive

Sigma-Aldrich and Goodfellow Cambridge join forces to distribute ceramics, metals and alloys

Sigma-Aldrich Corporation, a leading Life Science and High Technology Company, today announced the signing of an agreement with Goodfellow Cambridge, Ltd., a leading international supplier of metals and materials for research and industry, to market and distribute Goodfellow's portfolio of materials which includes metals, alloys and ceramics.

CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk

Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA).

‘When it starts getting into your local hospital, it becomes real'

The folding chairs outside the windows appeared late last month, after the maintenance staff at St. James Parish Hospital labeled each window with a patient room number so families and friends could at least see their loved ones battling COVID-19.

New technology developed at Cornell University could make it just as easy to identify genes

A supermarket checkout computer can identify thousands of different items by scanning the tiny barcode printed on the package. New technology developed at Cornell University could make it just as easy to identify genes, pathogens, illegal drugs and other chemicals of interest by tagging them with color-coded probes made out of synthetic tree-shaped DNA.

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

Read more Medical News

› Verified 7 days ago